Emergent BioSolutions | EBS - Trade Debtors


Emergent BioSolutions reported $290.1M in Trade Debtors for its fiscal quarter ending in June of 2023.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
ALKERMES USD 407.63M 73.6M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amarin USD 126.83M 477K Dec/2025
ANI Pharmaceuticals USD 255.43M 25.65M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Emergent BioSolutions USD 290.1M 134.2M Jun/2023
Exelixis USD 328.95M 42.03M Mar/2026
Glaxosmithkline GBP 10.45B 707.81M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
Lonza CHF 1.78B 55M Dec/2025
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Myriad Genetics USD 115.3M 2.7M Dec/2025
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Pacira USD 125.64M 1.57M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Xoma USD 14.78M 4.96M Jun/2024